The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...
BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...
Hosted on MSN9mon
Biogen buys California biotech for $1.15 billionor lab-made protein. It has generated promising results in clinical trials for treatment of kidney disorders that involve the immune system. Dr. Priya Singhal, Biogen’s head of development ...
US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche ... with Greek mythology from the name of the protein that is targeted by the RNAi drug ...
Hosted on MSN1mon
Biogen CEO sees no burning need for more acquisitionsSAN FRANCISCO (Reuters) - Biogen expects revenue from new launches ... an experimental drug that targets tau, a different protein found in the brains of Alzheimer's patients.
Biogen has revealed encouraging phase 2 results ... is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. It is thought that CD38-expressing ...
Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner ... deposits of a protein called amyloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results